Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of molecular subtype and race on HR+, HER2- breast cancer survival.
Reid S, Haddad D, Tezak A, Weidner A, Wang X, Mautz B, Moore J, Cadiz S, Zhu Y, Zheng W, Mayer IA, Shu XO, Pal T. Reid S, et al. Among authors: mayer ia. Breast Cancer Res Treat. 2021 Oct;189(3):845-852. doi: 10.1007/s10549-021-06342-0. Epub 2021 Jul 31. Breast Cancer Res Treat. 2021. PMID: 34331630 Free PMC article.
Does lapatinib work against HER2-negative breast cancers?
Mayer IA, Arteaga CL. Mayer IA, et al. Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179241 Free PMC article. Review.
Antiangiogenic therapies in early-stage breast cancer.
Derleth C, Mayer IA. Derleth C, et al. Among authors: mayer ia. Clin Breast Cancer. 2010;10 Suppl 1(Suppl 1):E23-31. doi: 10.3816/CBC.2010.s.004. Clin Breast Cancer. 2010. PMID: 20587404 Free PMC article. Review.
Molecular Heterogeneity of Triple Negative Breast Cancer.
Abramson VG, Mayer IA. Abramson VG, et al. Among authors: mayer ia. Curr Breast Cancer Rep. 2014 Sep 1;6(3):154-158. doi: 10.1007/s12609-014-0152-1. Curr Breast Cancer Rep. 2014. PMID: 25419441 Free PMC article.
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M, Ciruelos E, Garcia AA, Campana F, Wu B, Xu Y, Jiang J, Winer E, Krop I. Tolaney S, et al. Among authors: mayer ia. Breast Cancer Res Treat. 2015 Jan;149(1):151-61. doi: 10.1007/s10549-014-3248-4. Epub 2014 Dec 24. Breast Cancer Res Treat. 2015. PMID: 25537644 Clinical Trial.
184 results